24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Mori Arkin
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
17:38
Who will cover the damages of the largest computer failure in history?
16:00
Scopio Labs secures $42 million Series D for AI-based blood cell analysis
14:47
"Growing high-tech is essential for the economy of the North"
14:31
Full list of Israeli high-tech funding rounds in 2024
More stories
Buzz
Most popular
Daily
Weekly
1
The Gili Ra’anan model: Questions emerging from Cyberstarts' remarkable success
2
JPMorgan CEO Jamie Dimon makes whirlwind visit to Israel
3
From IPO dreams to CrowdStrike’s crisis: Inside the collapse of the Wiz-Google mega deal
4
Amdocs set to cut 1,500-3,000 jobs in new round of layoffs
5
Israel’s Quantum Transistors receives €17.5M from the European Innovation Council for its quantum computing solution
More news
Mori Arkin
5 stories about Mori Arkin
Exalenz Bioscience Acquired for $49M
19.02.20
|
Golan Hazani
Israeli-born billionaire & biomed entrepreneur Mori Arkin sold his company for 6.10 NIS per share. Learn more on CTech!
Biomed Entrepreneur Mori Arkin Nearing Sale of Exalenz to a U.S. Company
19.02.20
|
Golan Hazani
Tel Aviv-listed Exalenz is not considered one of the serial entrepreneur’s great successes, having lost 73% of its valuation over the past five years. The current deal will see it sold at a premium of tens of percentages, according to one source
Merck and WuXi AppTec Announce Launch of Biotech Incubator in Israel
20.02.18
|
Meir Orbach
The incubator program has a five year budget of 20 million euros
Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO
31.08.17
|
Dror Reich
The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology
Anti-Acne Drug Developer Plans Nasdaq IPO
15.08.17
|
Golan Hazani
Sol-Gel approached potential underwriters. It aims to go public before the end of the year
Please ensure Javascript is enabled for purposes of
website accessibility